FDA Moves on Peptides: What Compounding Pharmacies Need to Know The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and BPC 157 erectile dysfunction: What the evidence and user experiences actually show When will the FDA reclassify BPC 157 to Category 1 Octagon AI BREAKING: The FDA just made it official. Advisory committee meetings are now scheduled for July 23 24 to review reclassifying peptides back to legal compounding status. Here's what's happening: After the Bpc 157 bone healing: 2025's Crucial Warning.